New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
10:25 EDTABBV, ABBV, ABBV, RHHBY, RHHBY, RHHBY, PFE, PFE, PFE, PBYI, PBYI, PBYI, NVS, NVS, NVS, MDVN, MDVN, MDVN, LLY, LLY, LLY, JNJ, JNJ, JNJ, GSK, GSK, GSK, CLVS, CLVS, CLVS, CLDX, CLDX, CLDX, BMRN, BMRN, BMRN, AZN, AZN, AZN, AMGN, AMGN, AMGN, TSRO, TSRO, TSROLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts provide updates on breast cancer, in conjunction with the upcoming ASCO Annual Meeting, on an Analyst/Industry conference call to be held on May 20 at 11 am.
News For ABBV;AMGN;AZN;BMRN;CLDX;CLVS;GSK;JNJ;LLY;MDVN;NVS;PBYI;PFE;RHHBY;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 18, 2015
06:57 EDTNVSMallinckrodt says Questcor facing multi-state antitrust probe
Subscribe for More Information
06:50 EDTBMRNBioMarin price target raised to $151 from $140 at JPMorgan
Subscribe for More Information
06:00 EDTBMRNBioMarin price target raised to $156 from $150 at Barclays
Barclays raised its price target for BioMarin to $156 after vosoritide in a Phase 2 study showed a "clinically meaningful" 50% mean increase in annualized growth velocity for children with achondroplasia. The study, in effect, returned children with achondroplasia to normalized growth patterns, the firm tells investors. It views vosoritide as de-risk and keeps an Overweight rating on BioMarin. Piper this morning raised its price target for shares to $147.
05:54 EDTBMRNBioMarin price target raised to $147 from $123 at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer raised his price target for BioMarin shares to $147 after the company reported results from the Phase 2 trial of BMN111 in children with achondroplasia. The data showed an "impressive" 50% increase to the annualized grow rate of the children in high dose cohort, Schimmer tells investors in a research note. He views BMN111 as de-risked following the data and sees potential peak revenue of above $1B. Schimmer reiterates an Overweight rating on BioMarin. The stock is up $10.40 to $134.00 in pre-market trading.
June 17, 2015
16:38 EDTBMRNBioMarin trades higher in after hours session
Subscribe for More Information
16:26 EDTBMRNBioMarin up 6.5% after positive results from Phase 2 Vosoritide trial
Subscribe for More Information
16:07 EDTBMRNBioMarin 'very encouraged' by Phase 2 Vosoritide trial
Subscribe for More Information
12:02 EDTLLYEli Lilly reports LY2951742 meets primary endpoint in Phase 2b migraine study
Eli Lilly announced that its investigational medicine for prevention of migraine -- LY2951742, a CGRP neutralizing antibody -- met the primary endpoint in a Phase 2b study in episodic migraine. The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of four different doses of LY2951742 given in a once-monthly, subcutaneous injection in more than 400 patients with episodic migraine. The primary objective was to assess whether at least one dose of LY2951742 was superior to placebo in the prevention of migraine headache. LY2951742 demonstrated a statistically significant reduction in migraine headache days and a safety and tolerability profile confirming the previous results seen in a Phase 2a study. In addition to the migraine program, Lilly has initiated two Phase 3 trials with LY2951742 in patients suffering from cluster headache. Based on the unmet medical need and significance of this disorder for patients, Lilly has been granted fast track designation from the U.S. FDA for cluster headache.
10:00 EDTPFE, ABBV, LLYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:10 EDTLLYEli Lilly and Dana-Farber Cancer Institute enter research collaboration
Subscribe for More Information
08:02 EDTLLYEli Lilly partnering with Sarah Cannon Research Institute for oncology therapy
Eli Lilly and Sarah Cannon Research Institute announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
07:33 EDTABBVOraSure 44% year-to-date selloff overdone, says Jefferies
Subscribe for More Information
07:25 EDTABBV, PFE, LLYPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
07:21 EDTJNJGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
07:14 EDTRHHBYProthena announces PRX002 was safe, well tolerated
Subscribe for More Information
07:08 EDTMDVNMedivation, Astellas Pharma announce enrollment of first patients in TRUMPET
Subscribe for More Information
07:07 EDTMDVNMedivation and Astellas Pharma enroll first patients in prostate cancer registry
Astellas (ALPMY) and Medivation (MDVN) have enrolled the first patients in TRUMPET - Treatment Registry for Outcomes in CRPC Patients -, a prospective observational patient registry designed to better understand the unique needs and treatment patterns for patients with castration-resistant prostate cancer. The registry will enroll and evaluate 2,000 patients diagnosed with CRPC from urology and oncology sites across the U.S. TRUMPET is currently enrolling eligible patients and their caregivers; the study will be completed in 2020.
05:32 EDTABBVAbbVie initiated with an Overweight at Piper Jaffray
Subscribe for More Information
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
05:31 EDTLLYEli Lilly initiated with an Overweight at Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use